全文获取类型
收费全文 | 4854篇 |
免费 | 323篇 |
国内免费 | 38篇 |
专业分类
耳鼻咽喉 | 77篇 |
儿科学 | 151篇 |
妇产科学 | 102篇 |
基础医学 | 856篇 |
口腔科学 | 211篇 |
临床医学 | 462篇 |
内科学 | 836篇 |
皮肤病学 | 93篇 |
神经病学 | 674篇 |
特种医学 | 137篇 |
外科学 | 426篇 |
综合类 | 27篇 |
一般理论 | 2篇 |
预防医学 | 321篇 |
眼科学 | 182篇 |
药学 | 294篇 |
中国医学 | 23篇 |
肿瘤学 | 341篇 |
出版年
2024年 | 4篇 |
2023年 | 42篇 |
2022年 | 55篇 |
2021年 | 83篇 |
2020年 | 77篇 |
2019年 | 109篇 |
2018年 | 100篇 |
2017年 | 123篇 |
2016年 | 119篇 |
2015年 | 137篇 |
2014年 | 141篇 |
2013年 | 236篇 |
2012年 | 400篇 |
2011年 | 360篇 |
2010年 | 223篇 |
2009年 | 214篇 |
2008年 | 328篇 |
2007年 | 363篇 |
2006年 | 339篇 |
2005年 | 305篇 |
2004年 | 323篇 |
2003年 | 279篇 |
2002年 | 264篇 |
2001年 | 49篇 |
2000年 | 34篇 |
1999年 | 61篇 |
1998年 | 65篇 |
1997年 | 61篇 |
1996年 | 43篇 |
1995年 | 23篇 |
1994年 | 21篇 |
1993年 | 18篇 |
1992年 | 13篇 |
1991年 | 20篇 |
1990年 | 12篇 |
1989年 | 15篇 |
1988年 | 11篇 |
1987年 | 11篇 |
1986年 | 7篇 |
1985年 | 16篇 |
1984年 | 12篇 |
1983年 | 8篇 |
1982年 | 6篇 |
1981年 | 8篇 |
1980年 | 7篇 |
1978年 | 9篇 |
1977年 | 4篇 |
1943年 | 4篇 |
1927年 | 5篇 |
1924年 | 3篇 |
排序方式: 共有5215条查询结果,搜索用时 62 毫秒
61.
62.
Gwendlyn Kollmorgen Gerhard Niederfellner Alexander Lifke Gloria J. Spohn Natascha Rieder Suzana Vega Harring Frieder Bauss Helmut Burtscher Reiner Lammers Birgit Bossenmaier 《Molecular oncology》2013,7(6):1142-1151
CUB-domain-containing-protein-1 (CDCP1) is an integral membrane protein whose expression is up-regulated in various cancer types. Although high CDCP1 expression has been correlated with poor prognosis in lung, breast, pancreas, and renal cancer, its functional role in tumor formation or progression is incompletely understood. So far it has remained unclear, whether CDCP1 is a useful target for antibody therapy of cancer and what could be a desired mode of action for a therapeutically useful antibody. To shed light on these questions, we have investigated the cellular effects of a therapeutic antibody candidate (RG7287). In focus formation assays, prolonged RG7287 treatment prevented the loss of contact inhibition caused by co-transformation of NIH3T3 cells with CDCP1 and Src. In a xenograft study, MCF7 cells stably overexpressing CDCP1 reached the predefined tumor volume faster than the parental MCF7 cells lacking endogenous CDCP1. This tumor growth advantage was abolished by RG7287 treatment. In vitro, RG7287 induced rapid tyrosine phosphorylation of CDCP1 by Src, which was accompanied by translocation of CDCP1 to a Triton X-100 insoluble fraction of the plasma membrane. Triggering these effects required bivalency of the antibody suggesting that it involves CDCP1 dimerization or clustering. However, this initial activation of CDCP1 was only transient and prolonged RG7287 treatment induced internalization and down-regulation of CDCP1 in different cancer cell lines. Antibody stimulated CDCP1 degradation required Src activity and was proteasome dependent. Also in three different xenograft models with endogenous CDCP1 expression RG7287 treatment resulted in significant tumor growth inhibition concomitant with substantially reduced CDCP1 levels as judged by immunohistochemistry and Western blotting. Thus, despite transiently activating CDCP1 signaling, the RG7287 antibody has a therapeutically useful mode of action. 相似文献
63.
Mertens J Stock S Lüngen M V Berg A Kr?mer U Filipiak-Pittroff B Heinrich J Koletzko S Grübl A Wichmann HE Bauer CP Reinhardt D Berdel D Gerber A 《Pediatric allergy and immunology》2012,23(6):597-604
To cite this article: Mertens J, Stock S, Lüngen M, Berg AV, Kr?mer U, Filipiak-Pittroff B, Heinrich J, Koletzko S, Grübl A, Wichmann H-E, Bauer C-P, Reinhardt D, Berdel D, Gerber A. Is Prevention of Atopic Eczema with Hydrolyzed Formulas Cost-Effective? A Health Economic Evaluation from Germany. Pediatr Allergy Immunol 2012: 23: 597-604. ABSTRACT: Objective: The German Infant Nutritional Intervention (GINI) trial, a prospective, randomized, double-blind intervention, enrolled children with a hereditary risk for atopy. When fed with certain hydrolyzed formulas for the first 4?months of life, the risk was reduced by 26-45% in PP and 8-29% in intention-to-treat (ITT) analyses compared with children fed with regular cow's milk at age 6. The objective was to assess the cost-effectiveness of feeding hydrolyzed formulas. Patients and Methods: Cost-effectiveness was assessed with a decision tree model programmed in TreeAge. Costs and effects over a 6-yr period were analyzed from the perspective of the German statutory health insurance (SHI) and a societal perspective at a 3% effective discount rate followed by sensitivity analyses. Results: The extensively hydrolyzed casein formula would be the most cost-saving strategy with savings of 478?€ per child treated in the ITT analysis (CI95%: 12?€; 852?€) and 979?€ in the PP analysis (95%CI: 355?€; 1455?€) from a societal perspective. If prevented cases are considered, the partially whey hydrolyzed formula is cost-saving (ITT -5404?€, PP -6358?€). From an SHI perspective, the partially whey hydrolyzed formula is cost-effective, but may also be cost-saving depending on the scenario. An extensively hydrolyzed whey formula also included into the analysis was dominated in all analyses. Conclusions: For the prevention of AE, two formulas can be cost-effective or even cost-saving. We recommend that SHI should reimburse formula feeding or at least the difference between costs for cow's milk formula and the most cost-effective formula. 相似文献
64.
65.
66.
67.
68.
69.
70.